BioMarin Pharmaceutical Inc. (BMRN)

Oncology Corporate Profile

Stock Performance

87.7200
-0.9900

HQ Location

770 Lindaro Street
San Rafael, CA 94910

Company Description

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises five approved products and multiple clinical and pre-clinical product candidates.

Website: http://www.bmrn.com

Brand Generic Indication
Brineura™cerliponase alfaBrineura™ is a hydrolytic lysosomal N-terminal tripeptidyl peptidase indicated to slow the loss of ambulation in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase 1 (TPP1) deficiency.

This company does not have any pipeline products

Source: http://www.bmrn.com

Recent News Headlines

5/27/2017 06:17 am

5/27/2017 06:17 am

5/27/2017 06:17 am

5/27/2017 06:17 am

5/24/2017 06:17 am

5/24/2017 06:17 am

5/24/2017 06:17 am

5/24/2017 06:17 am

5/24/2017 06:17 am

5/12/2017 12:17 pm

5/12/2017 12:17 pm

5/12/2017 12:17 pm

5/12/2017 12:17 pm

5/10/2017 06:17 am

5/10/2017 06:17 am

5/10/2017 06:17 am

5/10/2017 06:17 am

5/10/2017 06:17 am

5/9/2017 12:17 pm

5/9/2017 06:17 am

5/8/2017 12:17 pm

5/4/2017 12:17 pm

5/4/2017 12:17 pm

5/4/2017 06:17 am

5/3/2017 06:17 am